MedPath
FDA Approval

OXLUMO

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
October 6, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Lumasiran(94.5 mg in 0.5 mL)

Manufacturing Establishments2

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Vetter Pharma-Fertigung GmbH & Co. KG

Alnylam Pharmaceuticals, Inc.

344217323

Ajinomoto Althea, Inc.

Alnylam Pharmaceuticals, Inc.

023050730

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

OXLUMO

Product Details

NDC Product Code
71336-1002
Application Number
NDA214103
Marketing Category
NDA (C73594)
Route of Administration
SUBCUTANEOUS
Effective Date
September 27, 2023
LumasiranActive
Code: RZT8C352O1Class: ACTIMQuantity: 94.5 mg in 0.5 mL
waterInactive
Code: 059QF0KO0RClass: IACT
Sodium hydroxideInactive
Code: 55X04QC32IClass: IACT
Phosphoric acidInactive
Code: E4GA8884NNClass: IACT
© Copyright 2025. All Rights Reserved by MedPath